Tesorai raised US$5.3 million in Seed funding, bringing its total raised to more than US$8 million. Perplexity Fund led the round with South Central Ventures and angel investors. The San Diego company builds AI tools that make life sciences research data searchable and reusable.
Early traction
Since raising a Pre-Seed round, Tesorai has signed contracts with biopharmaceutical and research organizations. It has collaborated with MD Anderson Cancer Center, NYU, and the Michael J. Fox Foundation. The company also received its first U.S. patent for one of its AI models.
Company background
Melissa Miao, Peter Cimermancic, and Charlie Kim co-founded Tesorai. They previously worked at Verily, Alphabet's life sciences company. Kim led the Molecular Science program there.
What the platform does
The platform processes raw experimental data, starting with mass spectrometry-based proteomics. It turns that data into structured, AI-ready datasets. Scientists and AI models can search and build on those datasets.
Tesorai plans to catalog more public repositories. It also plans to supply processed data to companies building AI models of biology. Researchers can try the platform for free at www.tesorai.com.